Oxis International Inc.

323 Vintage Park Drive, Suite B

Foster City, CA  92202  USA

Tel:  650-212-2568

Toll free:  800-547-3686

FAX: 650-212-2569

e-mail: info@oxis.com

 
 BioCheck products   |  Contract Manufacturing   |  Contact Us  
Oxis and Biocheck Joined Forces

2005 was a year of transition and growth for OXIS. During the second half of 2005 we acquired for $3 million in cash a 51% majority stake in privately held BioCheck, Inc., a leading manufacturer of immunoassay research services and products including test kits for cardiac and tumor markers and infectious diseases. In early 2006 we consolidated our operations at BioCheck’s manufacturing facility in Foster City, California. The combined OXIS BioCheck started 2006 in a good position to leverage the assets and talents within each organization, particularly in the areas of sales and marketing, manufacturing and product research and development.
About Biocheck

BioCheck, located in the San Francisco Bay Area, was founded in January 1997, to develop and manufacture high-quality enzyme immunoassay test kits for the worldwide biomedical, pharmaceutical, and scientific research markets. The founders have brought over four decades of experience, enabling BioCheck to quickly provide reliable and sensitive products to its customers.

Every BioCheck EIA kit is manufactured according to U.S. Food and Drug Administration (FDA) Good Manufacturing Practice standards in our 15,000 square foot facility in Foster City, California. At the present time, the company manufactures over 40 EIA test kits, of which 17 have been FDA cleared. The company also has U.S. FDA Certificates to Foreign Governments and Certificates of Exportability for many of its products.

BioCheck's EIA kits have also been registered in Brazil, India, Italy, Taiwan, Turkey, and the United Kingdom. We also work with distributors to deliver our products to countries in Central and South America, Europe, the Middle East, and Asia.

BioCheck is currently working with leading-edge biopharmaceutical companies to take advantage of advances in genomics in order to develop novel test kits that improve earlier and accurate detection of diseases.